10-21-06

IFW

Express Mail No.: ED 311 827 515 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Nielsen et al.

Application No.: 10/612,665

Filed: July 1, 2003

For: RECOMBINANT TISSUE PROTECTIVE CYTOKINES AND ENCODING NUCLEIC ACIDS THEREOF FOR PROTECTION, RESTORATION, AND ENHANCEMENT OF RESPONSIVE CELLS, TISSUES, AND ORGANS

Confirmation No.: 5726

Group Art Unit: 1646

Examiner: To Be Assigned

Attorney Docket No.: 10165-022-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **A01** to **A35, B01** to **B08**, and **C01** to **C122** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **B01** to **B08**, and **C01** to **C122** are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

The Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits; therefore, pursuant to 37 C.F.R. § 1.97(b)(3), no fee is believed due. However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: October 20, 2004

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

By: Eileen E. Falvey 46,097
Eileen E. Falvey (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 10165-022-999	APPLICATION NO 10/612,665
	APPLICANT Nielsen, et al.	
	FILING DATE July 1, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	2003/0072737 A1	04/17/03	Brines et al.			
	A02	2003/0040037 A1	02/27/03	Bayer			
	A03	2003/0003529 A1	01/02/03	Bayer			
	A04	2002/0160460 A1	10/31/02	Paulson et al.			
	A05	2002/0142370 A1	10/03/02	Paulson et al.			
	A06	6,489,293	12/3/02	Sytkowski, et al.			
	A07	6,399,336 B1	06/04/02	Paulson et al.			
	A08	6,165,783	12/26/00	Weiss et al.			
	A09	6,153,407	11/28/00	Sytkowski, et al.			
	A10	6,071,970	6/6/00	Mueller et al.			
	A11	6,048,971	4/11/00	Sytkowski, et al.			
	A12	5,955,422	9/21/99	Lin			
	A13	5,888,772	3/30/99	Okasinski et al.			
	A14	5,856,298	1/5/99	Strickland			
	A15	5,835,382	11/10/98	Wilson et al.			
	A16	5,830,851	11/3/98	Wrighton et al.			
	A17	5,773,569	6/30/98	Wrighton et al.			
	A18	5,767,078	6/16/98	Johnson et al.			
	A19	5,756,349	5/26/98	Lin			
	A20	5,714,459	2/3/98	O'Brien			
	A21	5,700,909	12/23/97	O'Brien			
	A22	5,696,080	12/9/97	O'Brien			
	A23	5,661,125	8/26/97	Strickland			
	A24	5,625,035	4/29/97	Clemons			
	A25	5,621,080	4/15/97	Lin			
	A26	5,618,698	4/8/97	Lin			
	A27	5,614,184	3/25/97	Sytkowski et al.			
	A28	5,604,198	2/18/97	Poduslo et al.			
	A29	5,571,787	11/5/96	O'Brien et al.			
	A30	5,547,933	8/20/96	Lin			
	A31	5,457,089	10/10/95	Fibi et al.			
	A32	4,835,260	5/30/89	Shoemaker			
	A33	4,806,524	2/21/89	Kawaguchi et al.			
	A34	4,703,008	10/27/87	Lin			
	A35	4,377,513	3/22/83	Sugimoto et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	5-246885	9/24/93	Japan				
	B02	WO 01/82953	11/8/01	PCT				
	B03	WO 01/82952	11/8/01	PCT				
	B04	WO 00/35475	6/22/00	PCT				
	B05	WO 98/18926	5/7/98	PCT				
	B06	WO 97/32895	12/12/97	PCT				
	B07	WO 97/18318	5/22/97	PCT				
	B08	WO 95/05465	2/23/95	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	C01	Alafaci *et al.*, 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar. 406:219-225
	C02	Anagnostou et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978
	C03	Annable *et al.*, 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. mond. Sante 47:99-112
	C04	Ashwell *et al.*, 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol. 50:287-291
	C05	Barber D.L. et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic activity," Blood, 98(11, part 2):132b-133b Abstract 4193
	C06	Bauer, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12
	C07	Benyo and Conrad, 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta," Biol. Reproduct. 60:861-870
	C08	Bernat et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS 100(3):952-957
	C09	Bernaudin et al., 2000, Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278
	C10	Bernaudin et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice," J. Cereb. Blood Flow Metab. 19:643-651
	C11	Biossel et al., 1993, "Erythropoietin structure-function relationships," J. Biol. Chem. 268(21):15983-15993
	C12	Bondy, 1995, "The relaxation of oxidative stress and hyperexcitation to neurological disease," Proc. Soc. Exp. Biol. Med. 208:337-345
	C13	Briggs et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227:1385-1388
	C14	Brines et al., 2000, "Erythropoietin crosses the blood-brain barrier to -protect against experimental brain injury," Proc. Natl. Acad. Sci. USA 97:10526-10531
	C15	Bruneval *et al.*, 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81:1593-1597
	C16	Camiscoli *et al.*, 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45
	C17	Campana et al., 1998, "Identification of a neurotrophic sequence in erythropoietin," Int. J. Mol. Med. 1:235-241
	C18	Claus-Walker and Dunn, 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374
	C19	Cotes, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17
	C20	Cotes and Bangham, 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760
	C21	Cotes and Bangham, 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067
	C22	Cunningham et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science 244(4908):1081-1085
	C23	Dale et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature 415:175-179
	C24	Digicaylioglu et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain," Proc. Natl. Acad. Sci. USA 92:3717-3720
	C25	Dipaolo et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin

		treatment," ASAIO J. 38:M477-M480
	C26	Dordal et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116:2293-2299
	C27	Dube et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263:17516-17521
	C28	Ehrenreich et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial," Molec. Med. 8(8):495-505
	C29	Elliott, et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502
	C30	Eur. Pharmacopoeia, 1997, pp. 5
	C31	Eur. Pharmacopoeia, Suppl. 2001, pp. 777-782
	C32	Farrell et al., 2001, "Erythropoietin crosses the blood brain barrier," Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)
	C33	Fukuda et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73:84-89
	C34	Garthoff, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711
	C35	Goldwasser et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97:315-323
	C36	Goldwasser and Gross, "Erythropoietin: Assay and Study of Its Mode of Action," Hormone Assays, pp. 109-121
	C37	Goldwasser et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249:4202-4206
	C38	Gorio et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma," Proc. Natl. Acad. Sci. USA 99:9450-9455 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.142287899)
	C39	Grasso et al., 2002, "Beneficial effects of systemic administration of recombinant human erythrpoietin in rabbits subjected to subarachnoid hemorrhage," Proc. Natl. Acad. Sci. USA 99:5627-5631
	C40	Gregory et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-x_L expression," Blood 94:87-96
	C41	Grimm et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin," Kidney Intl. 38:480-486
	C42	Gruber et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo," JBC 277(81):27581-27584
	C43	Hammond et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Erythropoietin, 149:516-527
	C44	Harris, K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319
	C45	Harris, K.W. "Signal Transduction in Myeloid Differentiation," Federal Research in Progress Database, FRP 03-05, ID No. 136456, Comp & Dist by NTIS
	C46	Harris, K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366
	C47	Hefti, 1997, "Pharmacology of neurotrophic factors," Annu. Rev. Pharmacol. Toxicol. 37:239-267
	C48	Hengemihle et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice," Physiol. Behav. 59:153-156
	C49	Hirakata et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO," Am. J. Physiol. 262:F737-F743
	C50	Horton et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754
	C51	Imai et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462
	C52	Junk et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury," Proc. Natl. Acad. Sci. USA 99:10659-10664 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.152321399)
	C53	Juul et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep," Soc. for Neuroscience Abstracts 27:929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)
	C54	Juul et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus," Early Human Devel. 52:235-249
	C55	Juul et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system," Pediatr. Res. 43:40-49
	C56	Keighley, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24
	C57	Kohama *et al.*, 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96:826-828
	C58	Konishi et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo," Brain Res. 609:29-35

	C59	Kopf et al., 1994, "Memory-improving actions of glucose: involvement of a central cholinergic muscarinic mechanism," Behav. Neural Biol. 62:237-243
	C60	Latini et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion," J. Cardiovasc. Pharmacol. 31:601-608
	C61	Li et al., 1998, "A single pre-training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor," Neurosci. 85:785-794
	C62	Li et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses," Pediatr. Res. 40:376-380
	C63	Linsley et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217
	C64	Lipinski et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats," Brain Res. 692:143-153
	C65	Liu et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain," J. Biol. Chem. 272:32395-32400
	C66	Liu et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression," Proc. Assoc. Am. Physicians 108:449-454
	C67	Liu et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice," Devel. Biol. 166:159-169
	C68	Lowy et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103
	C69	Marrero et al., 1998, "Erythropoietin receptor-operated Ca^{2+} channels: activation by phospholipase C-γ1," Kidney Intl. 53:1259-1268
	C70	Marsh et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients," Kidney Intl. 39:155-163
	C71	Marti et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain," Kidney Intl. 51:416-418
	C72	Marti et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain," Eur. J. Neurosci. 8:666-676
	C73	Masuda et al., 1997, "Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes," Brain Res. 746:63-70
	C74	Masuda et al., 1994, "A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes," J. Biol. Chem. 269:19488-19493
	C75	Masuda et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells," J. Biol. Chem. 268:11208-11216
	C76	Matsuyama *et al.*, 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202
	C77	Matthews et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS USA 93(18):9471-9476
	C78	Mioni et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells," Acta Endocrinologica 127:459-465
	C79	Miyake et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252:5558-5564
	C80	Morishita et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents *in vitro* glutamate-induced neuronal death," Neurosci. 76:105-116
	C81	Morrell *et al.*, 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo," J. Biol. Chem., 243:155-159
	C82	Moss and Scholey, 1996, "Oxygen administration enhances memory formation in healthy young adults," Psychopharmacol. 124:255-260
	C83	Nakamura et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients," Am. J. Med. Sci. 315:199-201
	C84	Nissenson et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects," Ann. Int. Med. 114:402-416
	C85	Nissenson, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life," Sem. Nephrol. 9(suppl. 2):25-31
	C86	Ogden, 1989, "Monitoring considerations in recombinant human erythropoietin therapy," Sem. Nephrol. 9(suppl. 2):12-15
	C87	Ohta et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography 910:1-11
	C88	Okada et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells," Digestion 57:328-332
	C89	Page et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69
	C90	Pardridge, 1997, "Drug delivery to the brain," J. Cerebral Blood Flow Metab. 17:713-731
	C91	Pardridge et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. 27:66-70

	C92	Park et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704
	C93	Peng et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Xue Bao (Acta Pharmaceutica Sinica) 35(10):764-769 Chinese
	C94	Poduslo et al., 1994, "Macromolecular premeability across the blood-nerve and blood-brain barriers," Proc. Natl. Acad. Sci. USA 91:5705-5709
	C95	Prendergast et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion," Pharmacol. Biochem. Behav. 57:347-352
	C96	Qiu et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176
	C97	Rose and Audus, 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells," Peptides 19:1023-1030
	C98	Rush et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452
	C99	Rush et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842
	C100	Sadamoto et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery," Biochem. Biophys. Res. Comm. 253:26-32
	C101	Sakanaka et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage," Proc. Natl. Acad. Sci. USA 95:4635-4640
	C102	Satake et al., 1990 "Chemical modification of erythropoietin: an increase in *in vitro* activity by guanidination," Biochim. Biophys Acta. 1038(1):125-129
	C103	Sawyer et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta," Blood 74:103-109
	C104	Shiramizu et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256
	C105	Shore et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48
	C106	Silva et al., 1999, "Erythropoietin can induce the expression of bcl-x_L through Stat5 in erythropoietin-dependent progenitor cell lines," J. Biol. Chem. 274:22165-22169
	C107	Sirén et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress," Proc. Natl. Acad. Sci. USA 98:4044-4049
	C108	Spivak and Hogans, 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood 73:90-99
	C109	Storring *et al.*, 1998, "Epoietin Alfa and Beta Differ In Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89
	C110	Storring and Gaines Das, 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," *J. Endocrinol.*, **134**:459-484.
	C111	Suzuki *et al.*, 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and ERythrocytosis," *British J. Haematology*, **113**:49-51.
	C112	Syed et al., 1998, "Efficiency of signalling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516
	C113	Tabira et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons *in vitro*", Int. J. Devl. Neurosci. **13**:241-252
	C114	Weiland *et al.*, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," 1982, *Blut*, **44**:173-175.
	C115	Wen et al., 1994, "erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846
	C116	Westenfelder et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. **55**:808-820
	C117	Williams et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. **718**:232-244
	C118	Wojchowski et al., 1989, "Biotinylated recombinant human erythropoietins: Bioactivity and utility as receptor ligand," Blood 74(3):952-958
	C119	Wolcott et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. **14**:478-485
	C120	Wolf et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509
	C121	Wu and Pardridge, 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", Neurobiol. **96**:254-259
	C122	Yamaji et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. **239**:494-500

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.